Is there a future for antiarrhythmic drug therapy?

Drugs

Volumn 56, Issue 5, 1998, Pages 767-781

  Guerra, Peter G ^a,b   Talajic, Mario ^a,b   Roy, Denis ^a,b   Dubuc, Marc ^a,b   Thibault, Bernard ^a,b   Nattel, Stanley ^a,b,c  

^a MONTREAL HEART INSTITUTE   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; AMIODARONE; ANTIARRHYTHMIC AGENT; CALCIUM ANTAGONIST; DIGOXIN; DILTIAZEM; DOFETILIDE; ESMOLOL; FLECAINIDE; IBUTILIDE FUMARATE; PROCAINAMIDE; PROPAFENONE; PROPRANOLOL; QUINIDINE; SOTALOL; VERAPAMIL;

ARTICLE; HEART ARRHYTHMIA; HEART ATRIOVENTRICULAR NODE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; REENTRY TACHYCARDIA;

EID: 0031789474     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199856050-00003     Document Type: Article

References (157)

1. Lewis T, Drury AN, Wedd AM, et al. Observations upon the action of certain drugs upon fibrillation of the auricles. Heart 1922; 9: 207-67
2. Viko LE, Marvin HM, White PD. A clinical report on the use of quinidine sulphate. Arch Intern Med 1923; 31 (3): 345-63
3. Kerr WMJ, Bender WML. Paroxysmal ventricular fibrillation with cardiac recovery in a case of auricular fibrillation and complete heart-block while under quinidine sulphate therapy. Heart 1922; 9: 269-81
4. Garrey WE. Auricular fibrillation. Physiol Rev 1924; 4: 215-50
5. Wiggers CJ. The mechanism and nature of ventricular defibrillation. Am Heart J 1940; 20: 399-412
6. Adgey AAJ, Scott ME, Allen JD, et al. Management of ventricular fibrillation outside hospital. Lancet 1969 Jun 14; 1: 1169-71
7. Southworth JL, McKusick VA, Peirce II EC, et al. Ventricular fibrillation precipitated by cardiac catheterization. JAMA 1950 Jun; 143 (8): 717-20
8. Lown B, Fakhro AM, Hood WB, et al. The coronary care unit: new perspectives and directions. JAMA 1967; 199: 188-98
9. Gianelly R, von der Groeben JO, Spivack AP, et al. Effect of lidocaine on ventricular arrhythmias in patients with coronary heart disease. N Engl J Med 1967 Dec 7; 277 (23): 1215-9
10. Lie KI, Wellens HJ, van Capelle FJ, et al. Lidocaine in the prevention of primary ventricular fibrillation: a double-blind, randomized study of 212 consecutive patients. N Engl J Med 1974 Dec 19; 291 (25): 1324-6
11. Bigger JT, Weld FM, Rolnitzky LM. Prevalence, characteristics and significance of ventricular tachycardia (three or more complexes) detected with ambulatory electrocardiographic recording in the late hospital phase of acute myocardial infarction. Am J Cardiol 1981 Nov; 48 (5): 815-23
12. Roden DM, Reele SB, Higgins SB, et al. Total suppression of ventricular arrhythmias by encainide: pharmacokinetic and electrocardiographic characteristics. N Engl J Med 1980 Apr 17; 302 (16): 877-82
13. Anderson JL, Stewart JR, Perry BA, et al. Oral flecainide acetate for the treatment of ventricular arrhythmias. N Engl J Med 1981 Aug 27; 305 (9): 473-7
14. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991 Mar 21; 324 (12): 781-8
15. Nattel S, Pedersen DH, Zipes DP. Alterations in regional myocardial distribution and arrhythmogenic effects of aprindine produced by coronary artery occlusion in the dog. Cardiovasc Res 1981; 15: 80-5
16. Coplen SE, Antman EM, Berlin JA, et al. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: a meta-analysis of randomized control trials. Circulation 1990 Oct; 82 (4): 1106-16
17. DiMarco JP, Miles W, Akhtar M, et al. Adenosine for paroxysmal supraventricular tachycardia: dose ranging and comparison with verapamil: assessment in placebo-controlled, multicenter trials. Ann Intern Med 1990 Jul; 113 (2): 104-10
18. Hood MA, Smith WM. Adenosine versus verapamil in the treatment of supraventricular tachycardia: a randomized double-crossover trial. Am Heart J 1992 Jun; 123: 1543-9
19. Madsen CD, Pointer JE, Lynch TG. A comparison of adenosine and verapamil for the treatment of supraventricular tachycardia in the prehospital setting. Ann Emerg Med 1995 May; 25 (5): 649-55
20. Cairns CB, Niemann JT. Intravenous adenosine in the emergency department management of paroxysmal supraventricular tachycardia. Ann Emerg Med 1991 Jul; 20 (7): 717-21
21. Rankin AC, Rae AP, Oldroyd KG, et al. Verapamil or adenosine for the immediate treatment of supraventricular tachycardia. Q J Med 1990 Feb; 74 (274): 203-8
22. Huycke EC, Sung RJ, Dias VC, et al. Intravenous diltiazem for termination of reentrant supraventricular tachycardia: a placebo-controlled, randomized, double-blind, multicenter study. J Am Coll Cardiol 1989 Mar; 13 (3): 538-44
23. Dougherty AH, Jackman WM, Naccarelli GV, et al. Acute conversion of paroxysmal supraventricular tachycardia with intravenous diltiazem. Am J Cardiol 1992 Sep; 70: 587-92
24. Boudonas G, Lefkos N, Efthymiadis AP, et al. Intravenous administration of diltiazem in the treatment of supraventricular tachyarrhythmias. Acta Cardiol 1995; 1 (2): 125-34
25. Sung RJ, Elser B, McAllister RG. Intravenous verapamil for termination of re-entrant supraventricular tachycardias: intracardiac studies correlated with plasma verapamil concentrations. Ann Intern Med 1980 Nov; 93 (5): 682-9
26. Hamer AWF, Strathmore N, Vohra JK, et al. Oral flecainide, sotalol, and verapamil for the termination of paroxysmal supraventricular tachycardia. PACE 1993 Jul; 16 (Pt 1): 1394-400
27. Goy JJ, Grbic M, Hurni M, et al. Conversion of supraventricular arrhythmias to sinus rhythm using flecainide. Eur Heart J 1985; 6: 518-24
28. Crozier IG, Ikram H, Kenealy M, et al. Flecainide acetate for conversion of acute supraventricular tachycardia to sinus rhythm. Am J Cardiol 1987 Mar; 59: 607-9
29. Sung RJ, Tan HL, Karagounis L, et al. Intravenous sotalol for the termination of supraventricular tachycardia and atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled study. Am Heart J 1995 Apr; 129 (4): 739-48
30. Winniford MD, Fulton KL, Hillis LD. Long-term therapy of paroxysmal supraventricular tachycardia: a randomized, double-blind comparison of digoxin, propranolol and verapamil. Am J Cardiol 1984 Nov; 54: 1138-9
31. Ganz LI, Friedman PL. Supraventricular tachycardia. N Engl J Med 1995 Jan 19; 332 (3): 162-73
32. Wu D, Denes P, Dhingra R, et al. The effects of propranolol on induction of A-V nodal reentrant paroxysmal tachycardia. Circulation 1974 Oct; 50: 665-77
33. Bauernfeind RA, Wyndham CR, Dhingra RC, et al. Serial electrophysiologic testing of multiple drugs in patients with atrioventricular nodal reentrant paroxysmal tachycardia. Circulation 1980 Dec; 62 (6): 1341-9
34. Wu D, Wyndham C, Amat-Y-Leon F, et al. The effects of ouabain on induction of atrioventricular nodal re-entrant paroxysmal supraventricular tachycardia. Circulation 1975 Aug; 52: 201-7
35. Gulamhusein S, Ko P, Carruthers SG, et al. Acceleration of the ventricular response during atrial fibrillation in the Wolff-Parkinson-White syndrome after verapamil. Circulation 1982 Feb; 65 (2): 348-54
36. Dorian P, Naccarelli GV, Coumel P, et al. A randomized comparison of flecainide versus verapamil in paroxysmal supraventricular tachycardia. Am J Cardiol 1996 Jan; 77 (25): A89-95
37. Anderson JL, Platt ML, Guarnieri T, et al. Flecainide acetate for paroxysmal supraventricular tachyarrhythmias. Am J Cardiol 1994 Sep; 74: 578-84
38. Podrid PJ, Anderson JL. Safety and tolerability of long-term propafenone therapy for supraventricular tachyarrhythmias. Am J Cardiol 1996 Aug; 78: 430-4
39. Chimienti M, Cullen MT, Casadei G. Report from the Flecainide and Propafenone Italian Study (FAPIS) group: safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Eur Heart J 1995; 16: 1943-51
40. Wanless RS, Anderson K, Joy M, et al. Multicenter comparative study of the efficacy and safety of sotalol in the prophylactic treatment of patients with paroxysmal supraventricular tachyarrhythmias. Am Heart J 1997 Apr; 133 (4): 441-6
41. Wellens HJJ, Brugada P, Abdollah H. Effect of amiodarone in paroxysmal supraventricular tachycardia with or without Wolff-Parkinson-White syndrome. Am Heart J 1983 Oct; 106 (4 Pt 2): 876-80
42. Suttorp MJ, Kingma JH, Lie-A-Huen L, et al. Intravenous flecainide versus verapamil for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. Am J Cardiol 1989 Mar; 63: 693-6
43. Suttorp MJ, Kingma JH, Jessurun ER, et al. The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. J Am Coll Cardiol 1990 Dec; 16 (7): 1722-7
44. Crijns HJGM, Van Gelder IC, Kingma JH, et al. Atrial flutter can be terminated by a class III antiarrhythmic drug but not by a class IC drug. Eur Heart J 1994; 15: 1403-8
45. Kingma JH, Suttorp MJ. Acute pharmacologic conversion of atrial fibrillation and flutter: the role of flecainide, propafenone, and verapamil. Am J Cardiol 1992 Aug; 70: A56-61
46. Bianconi L, Boccadamo R, Pappalardo A, et al. Effectiveness of intravenous propafenone for conversion of atrial fibrillation and flutter of recent onset. Am J Cardiol 1989 Aug; 64: 335-8
47. Tieleman RG, Gosselink ATM, Crijns HJGM, et al. Efficacy, safely, and determinants of conversion of atrial fibrillation and flutter with oral amiodarone. Am J Cardiol 1997 Jan; 79: 53-7
48. Suttorp MJ, Polak PE, van 't Hof A, et al. Efficacy and safety of a new selective class III antiarrhythmic agent dofetilide in paroxysmal atrial fibrillation or atrial flutter. Am J Cardiol 1992 Feb; 69: 417-9
49. Guo GBF, Ellenbogen KA, Wood MA, et al. Conversion of atrial flutter by ibutilide is associated with increased atrial cycle length variability. J Am Coll Cardiol 1996 Apr; 27 (5): 1083-9
50. Ellenbogen KA, Stambler BS, Wood MA, et al. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study. J Am Coll Cardiol 1996 Jul; 28 (1): 130-6
51. Volgman AS, Stambler BS, Kappagoda C, et al. Comparison of intravenous ibutilide versus procainamide for the rapid termination of atrial fibrillation or flutter [abstract]. PACE 1996 Apr; 19 (Pt II): 608
52. Stambler BS, Wood MA, Ellenbogen KA, et al. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation 1996 Oct; 94 (7): 1613-21
53. Tommaso C, McDonough T, Parker M, et al. Atrial fibrillation and flutter: immediate control and conversion with intravenously administered verapamil. Arch Intern Med 1983 May; 143: 877-81
54. Cowan JC, Gardiner P, Reid DS, et al. A comparison of amiodarone and digoxin in the treatment of atrial fibrillation complicating suspected acute myocardial infarction. J Cardiovasc Pharmacol 1986; 8 (2): 252-6
55. Crijns HJ, van Gelder IC, Lie KI. Supraventricular tachycardia mimicking ventricular tachycardia during flecainide treatmem. Am J Cardiol 1988 Dec; 62: 1303-6
56. Zipes DP. Specific arrhythmias: diagnosis and treatment. In: Braunwald E, editor. Heart disease: a textbook of cardiovascular medicine. 5th ed. Philadelphia: W.B. Saunders Company, 1997: 640-704
57. Borgeat A, Goy JJ, Maendly R, et al. Flecainide versus quinidine for conversion of atrial fibrillation to sinus rhythm. Am J Cardiol 1986 Sep; 58: 496-8
58. Hohnloser SH, van de Loo A, Baedeker F. Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine. J Am Coll Cardiol 1995 Oct; 26 (4): 852-8
59. Fenster PE, Comess KA, Marsh R, et al. Conversion of atrial fibrillation to sinus rhythm by acute intravenous procainamide infusion. Am Heart J 1983; 106 (3): 501-4
60. Halpern SW, Ellrodt G, Singh BN, et al. Efficacy of intravenous procainamide infusion in converting atrial fibrillation to sinus rhythm: relation to left atrial size. Br Heart J 1980; 44: 589-95
61. Capucci A, Lenzi T, Boriani G, et al. Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension. Am J Cardiol 1992 Jul; 70: 69-72
62. Crijns HJGM, van Wijk LM, van Gilst WH, et al. Acute conversion of atrial fibrillation to sinus rhythm: clinical efficacy of flecainide acetate. Comparison of two regimens. Eur Heart J 1988; 9: 634-8
63. Donovan KD, Dobb GJ, Coombs LJ, et al. Reversion of recent-onset atrial fibrillation to sinus rhythm by intravenous flecainide. Am J Cardiol 1991 Jan; 67: 137-41
64. Goy JJ, Kaufmann U, Kappenberger L, et al. Restoration of sinus rhythm with flecainide in patients with atrial fibrillation. Am J Cardiol 1988 Aug; 62: 38-40D
65. Porterfield JG, Porterfield LM. Therapeutic efficacy and safety of oral propafenone for atrial fibrillation. Am J Cardiol 1989 Jan; 63: 114-6
66. Abrams J, Allen J, Allin D, et al. Efficacy and safety of esmolol vs propranolol in the treatment of supraventricular tachyarrhythmias: a multicenter double-blind clinical trial. Am Heart J 1985 Nov; 110 (5): 913-22
67. Noc M, Stajer D, Horvat M. Intravenous amiodarone versus verapamil for acute conversion of paroxysmal atrial fibrillation to sinus rhythm. Am J Cardiol 1990 Mar; 65: 679-80
68. Blevins RD, Kerin NZ, Benaderet D, et al. Amiodarone in the management of refractory atrial fibrillation. Arch Intern Med 1987 Aug; 147: 1401-4
69. Donovan KD, Power BM, Hockings BEF, et al. Intravenous flecainide versus amiodarone for recent-onset atrial fibrillation. Am J Cardiol 1995; 75: 693-7
70. Galve E, Rius T, Ballester R, et al. Intravenous amiodarone in treatment of recent-onset atrial fibrillation: results of a randomized, controlled study. J Am Coll Cardiol 1996 Apr; 27 (5): 1079-82
71. Larbuisson R, Venneman I, Stiels B. The efficacy and safety of intravenous propafenone versus intravenous amiodarone in the conversion of atrial fibrillation or flutter after cardiac surgery. J Cardiothorac Vasc Anesth 1996 Feb; 10 (2): 229-34
72. Frost L, Mortensen PE, Tingleff J, et al. Efficacy and safety of dofetilide, a new class III antiarrhythmic agent, in acute termination of atrial fibrillation or flutter after coronary artery bypass surgery. Int J Cardiol 1997; 58: 135-40
73. Sedgwick ML, Lip G, Rae AP, et al. Chemical cardioversion of atrial fibrillation with intravenous dofetilide. Int J Cardiol 1995; 49: 159-66
74. Salerno DM, Dias VC, Kleiger RE, et al. Efficacy and safety of intravenous diltiazem for treatment of atrial fibrillation and atrial flutter. Am J Cardiol 1989 May; 63: 1046-51
75. Falk RH, Knowlton AA, Bernard SA, et al. Digoxin for converting recent-onset atrial fibrillation to sinus rhythm: a randomised, double-blinded trial. Ann Intern Med 1987 Apr; 106 (4): 503-6
76. Wang J, Bourne GW, Wang Z, et al. Comparative mechanisms of antiarrhythmic drug action in experimental atrial fibrillation: importance of use-dependent effects on refractoriness. Circulation 1993 Sep; 88 (3): 1030-44
77. Wang J, Feng J, Nattel S. Class III antiarrhythmic drug action in experimental atrial fibrillation: differences in reverse use dependence and effectiveness between d-sotalol and the new antiarrhythmic drug ambasilide. Circulation 1994 Oct; 90 (4): 2032-40
78. Nattel S. Newer developments in the management of atrial fibrillation. Am Heart J 1995; 130: 1094-106
79. Nattel S, Hadjis T, Talajic M. The treatment of atrial fibrillation: an evaluation of drug therapy, electrical modalities and therapeutic considerations. Drugs 1994; 48 (3): 345-71
80. Roy D, Talajic M, Thibault B, et al. Pilot study and protocol of the Canadian Trial of Atrial Fibrillation (CTAF). Am J Cardiol 1997 Aug; 80: 464-8
81. Mathew JP, Parks R, Savino JS et al. Atrial fibrillation following coronary artery bypass graft surgery: predictors, outcomes, and resource utilization. JAMA 1996 Jul; 276 (4): 300-6
82. Aranki SF, Shaw DP, Adams DH, et al. Predictors of atrial fibrillation after coronary artery surgery: current trends and impact on hospital resources. Circulation 1996 Aug; 94 (3): 390-7
83. Andrews TC, Reimold SC, Berlin JA, et al. Prevention of supraventricular arrhythmias after coronary artery bypass surgery: a meta-analysis of randomized control trials. Circulation 1991 Nov; 84 (5 Suppl. III): 111-236-44
84. Butler J, Harriss DR, Sinclair M, et al. Amiodarone prophylaxis for tachycardias after coronary artery surgery, a randomised, double-blind, placebo-controlled trial. Br Heart J 1993; 70: 56-60
85. Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992; 327 (4): 227-33
86. Emergency Cardiac Care Committee and Subcommittees, American Heart Association. Guidelines for cardiopulmonary resuscitation and emergency cardiac care: adult advanced cardiac life support. Part III. JAMA 1992 Oct 28; 268 (16): 2171-241
87. Nasir Jr N, Taylor A, Doyle TK, et al. Evaluation of intravenous lidocaine for the termination of sustained monomorphic ventricular tachycardia in patients with coronary artery disease with or without healed myocardial infarction. Am J Cardiol 1994 Dec; 74 (12): 1183-6
88. Gorgels APM, van den Dool A, Hofs A, et al. Comparison of procainamide and lidocaine in terminating sustained monomorphic ventricular tachycardia. Am J Cardiol 1996; 78: 43-6
89. Ho DSW, Zecchin RP, Richards DAB, et al. Double-blind trial of lignocaine versus sotalol for acute termination of spontaneous sustained ventricular tachycardia. Lancet 1994 Jul; 344: 18-23
90. Wolfe CL, Nibley C, Bhandari A, et al. Polymorphous ventricular tachycardia associated with acute myocardial infarction. Circulation 1991 Oct; 84 (4): 1543-51
91. Kowey PR, Marinchak RA, Rials SJ, et al. Electrophysiologic testing in patients who respond acutely to intravenous amiodarone for incessant ventricular tachyarrhythmias. Am Heart J 1993 Jun; 125 (6): 1628-32
92. Mitchell LB, Duff HJ, Manyari DE, et al. A randomized clinical trial of the noninvasive and invasive approaches to drug therapy of ventricular tachycardia. N Engl J Med 1987 Dec 31; 317 (27): 1681-7
93. ESVEM Investigators. The ESVEM Trial: electrophysiologic study versus electrocardiographic monitoring for selection of antiarrhythmic therapy of ventricular tachyarrhythmias. Circulation 1989 Jun; 79 (6): 1354-60
94. CASCADE Investigators. Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE Study). Am J Cardiol 1993 Aug; 72: 280-7
95. Kowey PR, Levine JH, Herre JM, et al. Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent, hemodynamically destabilizing ventricular tachycardia or fibrillation. Circulation 1995; 92: 3255-63
96. Nattel S. Antiarrhythmic drug classifications: a critical appraisal of their history, present status, and clinical relevance. Drugs 1991; 41 (5): 672-701
97. Nattel S, Waters D. What is an antiarrhythmic drug? From clinical trials to fundamental concepts. Am J Cardiol 1990 Jul; 66: 96-9
98. IMPACT Research Group. International mexiletine and placebo antiarrhythmic coronary trial: I. Report on arrhythmia and other findings. J Am Coll Cardiol 1984 Dec; 4 (6): 1148-63
99. Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction: an overview of results from randomized controlled trials. JAMA 1993 Oct; 270 (13): 1589-95
100. Waldo AL, Camm AJ, deRuyter H, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 1996 Jul 6; 348: 7-12
101. DIAMOND Study Group. Dofetilide in patients with left ventricular dysfunction and either heart failure or acute myocardial infarction: rationale, design, and patient characteristics of the DIAMOND studies. Clin Cardiol 1997 Aug; 20: 704-10
102. Nattel S, Talajic M. Recent advances in understanding the pharmacology of amiodarone. Drugs 1988 Aug; 36 (2): 121-31
103. Doval HC, Nul DR, Grancelli HO, et al. Randomised trial of low-dose amiodarone in severe congestive heart failure. Lancet 1994 Aug; 344: 493-8
104. Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 1995 Jul 13; 333 (2): 77-82
105. Burkart F, Pfisterer M, Kiowski W, et al. Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS). J Am Coll Cardiol 1990 Dec; 16 (7): 1711-8
106. Budaj A, Kokowicz P, Smielak-Korombel W, et al. Lack of effect of amiodarone on survival after extensive infarction. Coron Artery Dis 1996 Apr; 7 (4): 315-9
107. Cairns JA, Connolly SJ, Roberts R, et al. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Lancet 1997 Mar 8; 349: 675-82
108. Julian DG, Camm AJ, Frangin G, et al. Randomised trial of effect of amiodarone on mortality in patients with left ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997 Mar 8; 349: 667-74
109. Sim I, McDonald KM, Lavori PW, et al. Quantitative overview of randomized trials of amiodarone to prevent sudden cardiac death. Circulation 1997 Nov; 96 (9): 2823-9
110. Flaker GC, Blackshear JL, McBride R, et al. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. J Am Coll Cardiol 1992 Sep; 20 (3): 527-32
111. Hohnloser SH, Singh BN. Proarrhythmia with class III antiarrhythmic drugs: definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications. J Cardiovasc Electrophysiol 1995 Oct; 6 (Pt II) (10): 920-36
112. Roden DM, Woosley RL, Primm RK. Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. Am Heart J 1986 Jun; 111 (6): 1088-93
113. Roden DM, Thompson KA, Hoffman BF, et al. Clinical features and basic mechanisms of quinidine-induced arrhythmias. J Am Coll Cardiol 1986 Jul; 8 (1): 73-8A
114. Soyka LF, Wirtz C, Spangenberg RB. Clinical safety profile of sotalol in patients with arrhythmias. Am J Cardiol 1990 Jan; 65: 74-81A
115. MacNeil DJ, Davis RO, Deitchman D. Clinical safety profile of sotalol in the treatment of arrhythmias. Am J Cardiol 1993 Aug; 72: 44-50A
116. Falk RH. Proarrhythmia in patients treated for atrial fibrillation or flutter. Ann Intern Med 1992 Jul; 117 (2): 141-50
117. Winkle RA, Mason JW, Griffin JC, et al. Malignant ventricular tachyarrhythmias associated with the use of encainide. Am Heart J 1981; 102 (5): 857-63
118. Falk RH. Flecainide-induced ventricular tachycardia and fibrillation in patients treated for atrial fibrillation. Ann Intern Med 1989 Jul; 111 (2): 107-11
119. Lown B, Perloth MG, Bey SK, et al. 'Cardioversion' of atrial fibrillation: a report on the treatment of 65 episodes in 50 patients. N Engl J Med 1963; 269: 325-31
120. Lown B. Electrical reversion of cardiac arrhythmias. Br Heart J 1967 Jul; 29 (4): 469-89
121. Vassaux C, Lown B. Cardioversion of supraventricular tachycardias. Circulation 1969 Jun; 39: 791-802
122. Adgey AAJ, Patton JN, Campbell NPS, et al. Ventricular defibrillation: appropriate energy levels. Circulation 1979 Aug; 60 (2): 219-23
123. DeSilva RA, Graboys TB, Podrid PJ, et al. Cardioversion and defibrillation. Am Heart J 1980 Dec; 100 (6 Pt 1): 881-95
124. Kerber RE. Transthoracic cardioversion of atrial fibrillation and flutter: standard techniques and new advances. Am J Cardiol 1996 Oct; 78 Suppl. 8A: 22-6
125. Laupacis A, Albers G, Dalen J, et al. Antithrombotic therapy in atrial fibrillation. Chest 1995 Oct; 108 (4 Suppl.): 352-9S
126. Haissaguerre M, Warin JF, Lemetayer P, et al. Closed-chest ablation of retrograde conduction in patients with atrioventricular nodal reentrant tachycardia. N Engl J Med 1989 Feb 16; 320 (7): 426-33
127. Jazayeri MR, Hempe SL, Sra JS, et al. Selective transcatheter ablation of the fast and slow pathways using radiofrequency energy in patients with atrioventricular nodal reentrant tachycardia. Circulation 1992 Apr; 85 (4): 1318-28
128. Chen SA, Chiang CE, Tsang WP, et al. Selective radiofrequency catheter ablation of fast and slow pathways in 100 patients with atrioventricular nodal reentrant tachycardia. Am Heart J 1993 Jan; 125: 1-10
129. Mitrani RD, Klein LS, Hackett FK, et al. Radiofrequency ablation for atrioventricular node reentrant tachycardia: comparison between fast (anterior) and slow (posterior) pathway ablation. J Am Coll Cardiol 1993 Feb; 21 (2): 432-41
130. Calkins H, Sousa J, El-Atassi R, et al. Diagnosis and cure of the Wolff-Parkinson-White syndrome or paroxysmal supraventricular tachycardias during a single electrophysiologic test. N Engl J Med 1991 Jun; 324 (23): 1612-8
131. Jackman WM, Wang X, Friday KJ, et al. Catheter ablation of accessory atrioventricular pathways (Wolff-Parkinson-White syndrome) by radiofrequency current. N Engl J Med 1991 Jun; 324 (23): 1605-11
132. Kuck KH, Schlüter M, Geiger M, et al. Radiofrequency current catheter ablation of accessory atrioventricular pathways. Lancet 1991 Jun 29; 337: 1557-61
133. Simons GR, Klein GJ, Natale A. Ventricular tachycardia: pathophysiology and radiofrequency catheter ablation. PACE 1997 Feb; 20 (Part II): 534-51
134. Cox JL. The surgical treatment of atrial fibrillation. J Thorac Cardiovasc Surg 1991; 101: 584-92
135. Cox JL, Schuessler RB, D'Agostino HJ, et al. The surgical treatment of atrial fibrillation: III. Development of a definitive surgical procedure. J Thorac Cardiovasc Surg 1991; 101 (4): 569-83
136. Haïssaguerre M, Gencel L, Fischer B, et al. Successful catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol 1994 Dec; 5 (12): 1045-52
137. Haïssaguerre M, Jais P, Shah DC, et al. Right and left atrial radiofrequency catheter therapy of paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol 1996 Dec; 7 (12): 1132-44
138. Haïssaguerre M, Shah DC, Jaïs P, et al. Role of catheter ablation for atrial fibrillation. Curr Opin Cardiol 1997; 12: 18-23
139. Mirowski M, Mower MM, Staewen WS, et al. Standby automatic defibrillator: an approach to prevention of sudden coronary death. Arch Intern Med 1970; 126: 158-61
140. Moss AJ, Hall JW, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996 Dec 26; 335 (26): 1933-40
141. Antiarrhythmics versus implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997 Nov 27; 337 (22): 1576-83
142. Bigger JT. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. N Engl J Med 1997 Nov 27; 337 (22): 1569-75
143. Connolly SJ, Gent M, Roberts RS, et al. Canadian implantable defibrillator study (CIDS): study design and organization. Am J Cardiol 1993; 72: 103-8F
144. Ayers GM, Griffin JC. The future role of defibrillators in the management of atrial fibrillation. Curr Opin Cardiol 1997; 12: 12-7
145. + current similar to Kv1.5 cloned channel currents. Circ Res 1993; 73: 1061-76
146. + current in human atrial myocytes. Circ Res 1996; 78: 903-15
147. Amos GJ, Wettwer E, Metzger F, et al. Differences between outward currents of human atrial and subepicardial ventricular myocytes. J Physiol 1996; 491 (1): 31-50
148. Feng J, Wible B, Li GR, et al. Antisense oligonucleotides directed against Kv1.5 mRNA specifically inhibit ultrarapid delayed rectifier potassium current in cultured adult human atrial myocytes. Circ Res 1997; 80: 572-9
149. + channel cDNAs from human ventricle. FASEB J 1991; 5: 331-7
150. + channel current. Circ Res 1993; 73: 210-6
151. Wijffels MCEF, Kirchhof CJHJ, Dorland R, et al. Atrial fibrillation begets atrial fibrillation: a study in awake chronically instrumented goats. Circulation 1995; 92: 1954-68
152. Yue L, Feng J, Gaspo R, et al. Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation. Circ Res 1997; 81: 512-25
153. + current in a chronic dog model of atrial fibrillation. Circ Res 1997; 81: 1045-52
154. Goette A, Honeycutt C, Langberg JJ. Electrical remodeling in atrial fibrillation: time course and mechanisms. Circulation 1996; 94: 2968-74
155. Tieleman RG, De Langen CDJ, Van Gelder IC, et al. Verapamil reduces tachycardia-induced electrical remodeling of the atria. Circulation 1997; 95: 1945-53
156. Wang Q, Chen Q, Li H, et al. Molecular genetics of long QT syndrome from genes to patients. Curr Opin Cardiol 1997; 12: 310-20
157. Clark M, Friday K, Anderson J, et al. Drug induced torsades de pointes: high concordance rate among type IA antiarrhythmic drugs and amiodarone [abstract]. J Am Coll Cardiol 1985 Feb; 5 (2): 450